Flu Vaccines Market to Register Growth in Incremental Opportunity During the Forecast Period 2029

21/mag/2020 16:47:29 persistencemarketresearch Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

New York City, United States -- The change during the COVID-19 pandemic has overhauled our dependence on pattern setting developments, for instance, expanded reality, computer generated reality, and the Healthcare web of things. The unfulfilled cash related targets are persuading the relationship to grasp robotization and forefront advancements to stay ahead in the market competition. Associations are utilizing this open entryway by recognizing step by step operational needs and showing robotization in it to make an automated structure as far as might be feasible.

 

According to the latest research by Persistence Market, the global flu vaccine market is projected to account for a market value of approximately US$ 8 Bn by the end of 2029. Globally, increasing vaccination rate, and focus on preventive rather than reactive, is expected to drive the growth of the flu vaccine market. Increasing knowledge is due to the awareness drives taken by governments of various countries for the prevention of possible flu outbreaks, particularly in countries, which are more prone to flu pandemic.

Lower cost of flu vaccine plays a major role in the increasing vaccination rate across lower- and middle-income countries. The affordability of flu vaccine is due to World Health Organization’s tie ups with various regional flu vaccine manufacturers as well as major players.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/28720

Company Profiles:

  • Sanofi Pasteur Inc. (Sanofi S/A)
  • AstraZeneca
  • CSL Ltd. (Seqirus)
  • Abbott
  • GlaxoSmithKline Plc.
  • Serum Institute of India Pvt. Ltd.

The extended efforts by WHO, GAVI, and other organizations to stockpile flu vaccine for possible pandemics has helped improve the vaccination rate. The stockpiling of flu vaccines majorly depends upon various factors such as the possibility of a pandemic, the availability of insurance coverage during a possible pandemic, adequate supply & demand, and research & development.

In developing countries such as India, China, Brazil, etc., local manufacturers tend to develop a high volume of lower-cost vaccines, which helps enhance the reach of flu vaccines among the general population or population that is at a high risk of suffering from flu, which includes children, people aged over 65 years, and pregnant women.

The average time required for manufacturing vaccines and ensuring their availability in the market is around 2 years. However, flu vaccines are manufactured and launched in the market in a period of around a few months only (around 6 months). Thus, the ability of various pharmaceutical and biopharmaceutical companies to manufacture flu vaccines in a shorter duration is among the major drivers of the market.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/28720

In the Northern hemisphere, the manufacturing of flu vaccines begins in around February each year depending upon the WHO recommendations, whereas in the Southern hemisphere, it begins in around September. In 2004-2005, the global flu vaccine production capacity was around 1.6 billion doses, which increased to around 6.4 billion doses in 2018, thus, indicating an increase in the availability of the same across different regions of the world.

Manufacturers in the flu vaccine market are focusing on expanding their product offering in various countries by undergoing various activities such as partnerships, mergers & acquisitions, launch of new products, approvals, and agreements with various regional manufacturers.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/28720

For example, in December 2018, Sanofi developed a new vaccine, dubbed Vaxelis, in partnership with Merck. In 2015, AstraZeneca entered into a license agreement with Daiichi Sankyo for development and commercialisation of FluMist in Japan.

Persistence Market Research (PMR) has segmented the global flu vaccine market based on the product type, dosage form, distribution channel, and region. In terms of revenue, the quadrivalent flu vaccine segment is expected to be a prominent segment over the forecast period.

By dosage form, intramuscular remains preferred due to higher patient compliance. By distribution channel, sales of flu vaccines are likely to remain higher through institutional sales. The US remains the most lucrative market for flu vaccines market players.

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape

Liquid Chromatographymass Spectroscopy Market – Liquid Chromatography-Mass Spectroscopy Segmented By Triple Quadrupole, Time of Flight, Quadrupole Technology in Clinical Testing, Environmental Testing, Forensic TestingFor More Information

Biopharmaceutical Market – Biopharmaceuticals Market Segmented By Monoclonal Antibodies, Recombinant Proteins, Granulocyte-Colony Stimulating Factor, Interferons, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins Type for Metabolic Disorders, Oncology, Neurological Disorders, Cardiovascular Diseases, Inflammatory and Infectious DiseasesFor More Information

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish Kolte
Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl